Key points A 40-year-old man was referred to our internal medicine clinic for assessment of a 3-month history of unintentional weight loss and daily night sweats with subjective fevers. He had been ...
Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease. A preliminary analysis ...
CRANBURY, NJ, USA I March 28, 2025 I Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...
ABIVAX is a French biotech with a novel ulcerative colitis treatment in phase 3 trials. Click here to find out why I am ...
Verywell Health on MSN3d
What Does Magnesium Oil Do, and Should You Add It to Your Routine?Medically reviewed by Sohaib Imtiaz, MD Magnesium is an essential mineral that is involved in more than 300 body processes, ...
Vitamin B12 is a vital nutrient responsible for red blood cell formation, nerve health, and the creation of DNA. Even though ...
Whenever gluten is consumed in people with celiac disease, the immune system will view the protein as harmful and launch an inflammatory attack, damaging villi. Crohn's disease is a type ... When ...
Silent Crohn’s disease may have little or no symptoms. It's important to monitor disease activity and treat the condition to ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback